Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS

Authors

DOI:

https://doi.org/10.22376/ijlpr.v16i3.2059

Keywords:

Abbreviated new drug application, Generic antiviral drugs, Bioequivalence, Drug registration, Acyclovir, Oseltamivir phosphate, Regulatory affairs, BRICS countries, Common Technical Document

Abstract

Generic antiviral medicines widened access to treatment for chronic and epidemic viral infections once patents on branded products expired. Approval requirements for generic medicines differed between countries, and earlier comparisons either described frameworks that were later replaced or gave little attention to antiviral-specific bioequivalence expectations. This study compares the abbreviated new drug application pathway of the United States Food and Drug Administration with generic drug registration in Brazil, Russia, India, China and South Africa, and it illustrates product-specific bioequivalence expectations for two antivirals, acyclovir topical cream and oseltamivir phosphate capsules. The novelty of the study lies in combining country-level procedures with antiviral case studies and in correcting superseded descriptions found in earlier compilations. The work is a descriptive comparative review. Regulatory instruments, regulator publications, product-specific guidances and published comparative studies are compiled, and six parameters (regulator, legal basis, dossier format and language, review structure, bioequivalence approach and indicative review duration) are tabulated for each country. Time-sensitive items are checked against notices current in November 2026. No statistical analysis is applicable to this descriptive study. All six jurisdictions use a dossier organised on the Common Technical Document and require proof of bioequivalence to a reference product, but they differ in legal basis, language, review structure, reliance on assessments by other regulators, patent-linkage mechanisms and reported review duration. Earlier descriptions are superseded in several respects: the Chinese and South African regulators have been renamed, Russia registers medicines under Eurasian Economic Union rules, the Brazilian generic requirements are consolidated in a 2022 resolution, and the Indian rules of 2019 replaced Schedule Y. The acyclovir case shows that a topical product can be approved through formulation sameness with in vitro release testing or through a clinical endpoint study, whereas the oseltamivir case shows that an oral capsule can be approved through a biowaiver based on the Biopharmaceutics Classification System or through fasting and fed crossover studies. Convergence on the Common Technical Document and on bioequivalence principles lowers the barrier to multi-country filing, but national legal instruments, language, timelines and product-specific expectations still require a jurisdiction-specific strategy.

References

De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016 Jul;29(3):695-747.

Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, Akram M, Riaz M, Rasool G, et al. A review: mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol. 2021 Mar;35:20587384211002621.

Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). Pub. L. No. 98-417, 98 Stat. 1585 (1984).

U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA) [Internet]. Silver Spring (MD): FDA; [Accessed on 2026 Nov 10]. Available from: https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

Electronic Code of Federal Regulations. Title 21, Part 320: Bioavailability and bioequivalence requirements [Internet]. [Accessed on 2026 Nov 10]. Available from: https://www.ecfr.gov

Sravika S, Bhavana R, Sharmila V, Anusha S, Mounica NVN, Reddy DN, et al. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. Pharma Innov. 2017 Apr 1;6(4 Pt C):153.

Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. Int J Pharm Investig. 2012 Jul;2(3):99.

Tejorani M, Bonthagarala B, Ramakrishna G, Nagabhushanam M. Comparative studies for filing and marketing authorisation of generic drugs in Europe, United States and India. Indo Am J Pharm Sci. 2021:165-73. doi:10.5281/zenodo.5225920

Kavitha M. A review on generic drugs registration procedure in USA & Canada. World J Pharm Res. 2017:452-63. doi:10.20959/wjpr20177-8722

Badjatya JK. Regulatory requirements and registration process of generic drugs in China. PharmaTutor. 2016 Feb 1;4(2):13-8.

Deore D, Patel P. Comparative overview of registration and approval process for generic drugs in BRICS countries. Int J Drug Regul Aff. 2022;10:40-50. doi:10.22270/ijdra.v10i1.509

Hasan MI, Shimu SA, Akther A, Jahan I, Hamiduzzaman M, Hasan AN. Development of generic drug products by pharmaceutical industries considering regulatory aspects: a review. J Biosci Med. 2021 Sep 30;9(10):23-39.

U.S. Food and Drug Administration. Product-specific guidance for acyclovir (topical cream) [Internet]. Silver Spring (MD): FDA; [Accessed on 2026 Nov 10]. Available from: https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm

U.S. Food and Drug Administration. Product-specific guidance for oseltamivir phosphate (oral capsule) [Internet]. Silver Spring (MD): FDA; [Accessed on 2026 Nov 10]. Available from: https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm

Grand View Research. Antiviral drugs market size, share & growth report, 2030 [Internet]. San Francisco: Grand View Research; [Accessed on 2026 Nov 10]. Available from: https://www.grandviewresearch.com

Electronic Code of Federal Regulations. Title 21, Part 314: Applications for FDA approval to market a new drug [Internet]. [Accessed on 2026 Nov 10]. Available from: https://www.ecfr.gov

U.S. Food and Drug Administration. GDUFA reauthorization performance goals and program enhancements, fiscal years 2023-2027 (GDUFA III commitment letter) [Internet]. Silver Spring (MD): FDA; [Accessed on 2026 Nov 10]. Available from: https://www.fda.gov/media/153631/download

U.S. Food and Drug Administration. Generic drug user fee rates for fiscal year 2027. Fed Regist [Internet]. 2026 Jul 30 [Accessed on 2026 Nov 10]; Doc. 2026-15343. Available from: https://www.federalregister.gov/documents/2026/07/30/2026-15343/generic-drug-user-fee-rates-for-fiscal-year-2027

U.S. Food and Drug Administration. Notice on reauthorization of the Generic Drug User Fee Amendments for fiscal years 2028 to 2032. Fed Regist [Internet]. 2026 [Accessed on 2026 Nov 10]; Doc. 2026-16353. Available from: https://public-inspection.federalregister.gov/2026-16353.pdf

Brazil. Lei n. 9.787 de 1999, que altera a Lei n. 6.360, de 23 de setembro de 1976, sobre medicamentos genericos [Law No. 9,787 of 1999 amending Law No. 6,360 of 23 September 1976 on generic medicines]. Brasilia: Presidencia da Republica.

Agencia Nacional de Vigilancia Sanitaria (Anvisa). Resolucao da Diretoria Colegiada RDC n. 753, de 28 de setembro de 2022. Diario Oficial da Uniao. 2022 Oct 5;(190) [Internet]. [Accessed on 2026 Nov 10]. Available from: https://www.gov.br/anvisa/en/rules-and-regulations/arquivos/rdc-753_2022.pdf

Eurasian Economic Commission Council. Decision No. 78 of 3 November 2016 on the Rules of registration and evaluation of medicines for medical use. Moscow: Eurasian Economic Commission; 2016.

Eurasian Economic Commission Council. Decision No. 85 of 3 November 2016 on the Rules for conducting bioequivalence studies of medicinal products within the Eurasian Economic Union. Moscow: Eurasian Economic Commission; 2016.

ALRUD. Head start to 2021 for the pharmaceutical industry in Russia [Internet]. Moscow: ALRUD; [Accessed on 2026 Nov 10]. Available from: https://alrud.com/publications/854

Ministry of Health and Family Welfare, Government of India. New Drugs and Clinical Trials Rules, 2019 (as amended) [Internet]. New Delhi: Central Drugs Standard Control Organisation; [Accessed on 2026 Nov 10]. Available from: https://cdsco.gov.in

Medical Dialogues. Unequal trials in new drug approvals: CDSCO seeks feedback for policy reform [Internet]. [Accessed on 2026 Nov 10]. Available from: https://medicaldialogues.in/amp/news/industry/pharma/cdsco/unequal-trials-in-new-drug-approvals-cdsco-seeks-feedback-for-policy-reform-156638

Cisema. NMPA issues new "Chemical Drug Registration Acceptance Review Guidelines" to standardize drug registration process [Internet]. 2025 Apr 9 [Accessed on 2026 Nov 10]. Available from: https://cisema.com/news/chemical-drug-registration-nmpa-guidelines

South African Health Products Regulatory Authority. Medical products backlog clearance strategy [Internet]. Pretoria: SAHPRA; [Accessed on 2026 Nov 10]. Available from: https://sahpra.org.za/backlog

Published

2026-11-13

How to Cite

Mangilipally, S., Lingala, D., Dusa, J., S, A. T., Bogi, N., Aeluka, R., & D, P. (2026). Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS. International Journal of Life Science and Pharma Research, 16(3), 64–75. https://doi.org/10.22376/ijlpr.v16i3.2059

Issue

Section

Research Articles